Please assess the completion status of the following clinical trial:

Trial Title: TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* First post-transplant squamous cell carcinoma in a kidney transplant recipient under calcineurin inhibitors~Exclusion Criteria:~* Other squamous cell carcinomas in the past history~* More than 2 transplantations~* Patients not under calcineurin inhibitors~* Unstable graft function~* Non controlled hyperlipidemia (cholesterol \> 7.8 mmol/l or triglycerides \> 3.95 mmol/l)~* Leucopenia \< 3000/mm3~* Thrombocytopenia \< 100,000/mm3~* Liver dysfunction~* Pregnancy~* Allergy to macrolides

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): patients receiving Rapamycin
- 2 (Type: ACTIVE_COMPARATOR): patients receiving anticalcineurin treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).